Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Sep 19, 2011
Company News
Via Science, Brigham and Women's Hospital deal
...using data from over 18,000 patients with congestive heart failure (CHF). Terms were not disclosed.
Via Science Inc.
...
Read More
BioCentury
|
Aug 15, 2011
Company News
Via Science, Bristol-Myers deal
...therapies for specific genetic and phenotypes to optimize individualized patient outcomes. Details were not disclosed.
Via Science Inc.
...
Read More
BioCentury
|
Jul 18, 2011
Company News
Via Science, National Cancer Institute deal
...response to drug treatments for the development of more effective treatments. Details were not disclosed.
Via Science Inc.
...
Read More
Items per page:
10
1 - 3 of 3
BioCentury
|
Sep 19, 2011
Company News
Via Science, Brigham and Women's Hospital deal
...using data from over 18,000 patients with congestive heart failure (CHF). Terms were not disclosed.
Via Science Inc.
...
Read More
BioCentury
|
Aug 15, 2011
Company News
Via Science, Bristol-Myers deal
...therapies for specific genetic and phenotypes to optimize individualized patient outcomes. Details were not disclosed.
Via Science Inc.
...
Read More
BioCentury
|
Jul 18, 2011
Company News
Via Science, National Cancer Institute deal
...response to drug treatments for the development of more effective treatments. Details were not disclosed.
Via Science Inc.
...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page